David C. Norris

This paper evaluates the efficiency of one-size-fits-all versus individualized dosing in combination therapies using simulations, finding that pragmatic titration is more efficient than POCRM.

This paper estimates the societal cost of one-size-fits-all dosing in oncology trials by comparing it to individualized MTDi dosing using simulated data.